New cell therapy takes on Hard-to-Treat cancers
NCT ID NCT07166263
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial will test NK510, a cell therapy, in 15 people with advanced stomach or colorectal cancer that has come back or not responded to at least two prior treatments. NK510 is given through an IV or directly into the abdomen. The main goals are to check safety and see if the treatment can shrink tumors or slow the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NK510 cell therapy
- What this could lead to
- If it works, this could point toward a new treatment option for advanced gastric and colorectal cancers that have not responded to other therapies.
- What could go wrong
- This is a very early, small trial with only 15 participants. The treatment may not work or could have serious side effects. Success in this phase does not guarantee broader effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nanjing Drum Tower Hospital, Affiliated to the Medical School of Nanjing University
Nanjing, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?